Panel A shows a visual timeline that includes sample collection points at T0, T1, and T2, with vaccinations PCV13 and PPSV23, and eculizumab initiation. Panel B presents line graphs showing the kinetics of pneumococcal serotype-specific IgG concentrations. The left graph for patient P5 shows three-point curves at T0 (baseline), T1 (60 days after vaccination), and T2 (60 days after eculizumab initiation). The right graph for patient P8 shows two-point curves at T0 and T2. T cell-dependent PCV13 serotypes are shown in shades of blue, while T cell-independent PPSV23 serotypes 8 and 9N are shown in orange and red, respectively. Panel C includes radar charts and bar charts illustrating IgG concentrations against individual pneumococcal serotypes in patients P5, P6, and P8 two months after eculizumab treatment. The radar charts display the IgG titers for each serotype, and the bar charts compare the IgG concentrations across different serotypes for the three patients.
Impact of eculizumab timing on serotype-specific IgG responses to PCV13 and PPSV23 vaccination. (A) Visual timeline of vaccination, eculizumab initiation, and pneumococcal serotype–specific IgG titer assessment in patients P5, P6, and P8. (B) Kinetics of pneumococcal serotype–specific IgG concentrations following sequential PCV13 and PPSV23 vaccination and eculizumab therapy. The left panel shows longitudinal three-point curves of IgG concentrations at T0 (baseline), T1 (60 days after sequential PCV13 and PPSV23 vaccination, prior to eculizumab), and T2 (60 days after eculizumab initiation) in patient P5. The right panel shows two-point curves of IgG titers at baseline (T0) and 60 days after eculizumab initiation (T2) in patient P8. T cell–dependent PCV13 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) are shown in shades of blue, whereas T cell–independent PPSV23 serotypes 8 and 9N are shown in orange and red, respectively. (C) IgG concentrations against individual pneumococcal serotypes in patients P5, P6, and P8 2 mo after eculizumab treatment, illustrated as radar charts and bar charts. PCV13: 13-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.